The recently announced global license agreement with Novartis to advance VAV1-directed MGDs for immune-related conditions marks a transformative milestone towards that goal,” said Markus Warmuth, M.D.

According to the agreement, Vindur Tx will pay Optic up to $17.5 million for its proprietary technology to explore new ways of addressing previously "undruggable" targets in difficult-to-treat cancers ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

“As the year progresses, the market will continue to outperform expectations. Real estate transactions are more robust than last year, with month-on-month growth. The market has demonstrated ...

Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

The Master Services Agreement (MSA) and Clinical Supply Agreement with Nucleus RadioPharma complement the existing agreement with NorthStar Medical Radioisotopes, LLC (NorthStar) for 67Cu-SAR-bisPSMA ...

Doctors have been fairly quick to jump on the biologics train: According to Spherix, 96% of dermatologists reported using ...

Watch out, Gilead and Novartis: there's a new CAR-T in town. Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy ...

Analyst Thomas Smith of Leerink Partners reiterated a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report), retaining the ...

Women aged less than 50 years hospitalized with MI have gender-specific cardiovascular risk factors and experience typical chest pain.

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...